Source comparison
BPC-157 for Meniscus Injury: Treatment Protocol Comparison
BPC-157 Subcutaneous Injection Upregulates VEGF and FGF-2; promotes angiogenesis and collagen synthesis at injury sites 4–8 weeks (daily or twice-daily injections) Preclinical only—robust animal data, no human RCTs Promising tissue repair mechanism but lacks F
This comparison does not assign a generated winner or score.
- BPC-157 Subcutaneous Injection
- Upregulates VEGF and FGF-2; promotes angiogenesis and collagen synthesis at injury sites
- 4–8 weeks (daily or twice-daily injections)
- Preclinical only—robust animal data, no human RCTs
- Promising tissue repair mechanism but lacks FDA approval; investigational use only
- NSAIDs (Ibuprofen, Naproxen)
- COX enzyme inhibition; reduces prostaglandin synthesis and acute inflammation
- 7–14 days (short-term symptom management)
- Extensive human data—effective for pain but may delay tissue healing
- Pain relief confirmed, but prolonged use inhibits collagen synthesis—contraindicated for tissue repair
- Platelet-Rich Plasma (PRP) Injection
- Delivers concentrated growth factors (PDGF, TGF-beta) directly to injury site
- Single injection or series (1–3 injections over 4–6 weeks)
- Moderate—some human trials show benefit in red-zone tears; white-zone results inconsistent
- Most effective for vascularized meniscal zones; limited utility in avascular tears
- Physical Therapy + Load Management
- Restores joint mechanics, strengthens stabilizers, offloads damaged tissue during healing
- 8–12 weeks minimum (progressive loading protocol)
- High—gold standard for conservative meniscus management; RCT-supported
- Essential regardless of adjunct therapy—no peptide or injection replaces controlled rehabilitation
- BPC-157 for meniscus injury occupies a narrow investigational niche. It's not a replacement for mechanical load management or structured rehabilitation—those remain non-negotiable for any connective tissue healing protocol.